scholarly article | Q13442814 |
P2093 | author name string | Rowland M | |
Tanaka C | |||
Kawai R | |||
Mathew D | |||
P433 | issue | 2 | |
P921 | main subject | pharmacokinetics | Q323936 |
cyclosporine | Q367700 | ||
P304 | page(s) | 457-468 | |
P577 | publication date | 1998-11-01 | |
P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
P1476 | title | Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human | |
P478 | volume | 287 |
Q89482511 | A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts |
Q46777776 | A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide |
Q36445112 | A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans |
Q37470663 | A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine |
Q46769353 | A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate |
Q35888381 | A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding |
Q50722759 | A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. |
Q43840428 | A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin |
Q31017890 | Analyzing multi-response data using forcing functions |
Q51761715 | Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. |
Q33383176 | Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression |
Q43767845 | Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential |
Q43663687 | Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants |
Q34749073 | Distribution of cyclosporin in organ transplant recipients |
Q37246076 | Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. |
Q28473451 | Drug-class specific impact of antivirals on the reproductive capacity of HIV |
Q36693701 | Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs |
Q42185186 | Human structural proteome-wide characterization of Cyclosporine A targets |
Q27022933 | ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans |
Q40905288 | Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations |
Q42919793 | Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model |
Q39192461 | Interpreting copper bioaccumulation dynamics in tilapia using systems-level explorations of pulsed acute/chronic exposures |
Q37504548 | Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver |
Q51919468 | Mechanistic approaches to volume of distribution predictions: understanding the processes. |
Q82100906 | Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat |
Q50698909 | Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. |
Q41368460 | Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity |
Q50476254 | Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate |
Q51905139 | Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution. |
Q49091990 | Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats |
Q37619315 | Physiologically-based PK/PD modelling of therapeutic macromolecules |
Q88404781 | Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics |
Q37820451 | Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. |
Q36204764 | Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice |
Q37802266 | Prediction of Exposure–Response Relationships to Support First-in-Human Study Design |
Q42129809 | Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats |
Q30327851 | The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'. |
Q57295021 | The use of PBPK modeling across the pediatric age range using propofol as a case |
Q89982792 | Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids |
Q42739574 | Use of dried blood spots in drug development: pharmacokinetic considerations |
Q42242976 | Use of partition coefficients in flow-limited physiologically-based pharmacokinetic modeling |
Q35186644 | Whole body pharmacokinetic models |
Search more.